Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Annovis Bio Inc has a consensus price target of $36.71 based on the ratings of 7 analysts. The high is $67 issued by Rodman & Renshaw on July 2, 2024. The low is $9 issued by Brookline Capital on February 28, 2024. The 3 most-recent analyst ratings were released by EF Hutton, HC Wainwright & Co., and EF Hutton on August 15, 2024, August 15, 2024, and August 13, 2024, respectively. With an average price target of $24 between EF Hutton, HC Wainwright & Co., and EF Hutton, there's an implied 199.63% upside for Annovis Bio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Annovis Bio (NYSE:ANVS) was reported by EF Hutton on August 15, 2024. The analyst firm set a price target for $21.00 expecting ANVS to rise to within 12 months (a possible 147.93% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Annovis Bio (NYSE:ANVS) was provided by EF Hutton, and Annovis Bio maintained their buy rating.
There is no last upgrade for Annovis Bio
The last downgrade for Annovis Bio Inc happened on February 28, 2024 when Brookline Capital changed their price target from N/A to $9 for Annovis Bio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Annovis Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Annovis Bio was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.
While ratings are subjective and will change, the latest Annovis Bio (ANVS) rating was a maintained with a price target of $21.00 to $21.00. The current price Annovis Bio (ANVS) is trading at is $8.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.